Table 4. Summary of major trials involving Belimumab.

Drug	Significant Trials	Findings
Belimumab: Human anti-BlyS monoclonal antibody (intravenous or subcutaneous)	BLISS-52 and BLISS-76 [21,22]	-Multicenter, double-blind placebo-controlled trials. -Primary endpoints were achieved in both with significant improvement in SRI scores in both. -Reduced Corticosteroid dosage and disease flare and activity were observed. -Subgroup analysis revealed improvement in Lupus nephritis
	BLISS-LN [27]	This was a phase 3, multinational, randomized, double-blind, placebo-controlled involving patients with active nephritis. -Primary endpoint was achieved after induction treatment with HDCS and MMF in lupus nephritis class 111, 1V.
	EMBRACE Trial [26]	A multicenter, double-blind, placebo-controlled trial in adults of Black race with active SLE. -The primary endpoint was not achieved - Corticosteroid tapering was possible in BEL group